JP2020506943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506943A5 JP2020506943A5 JP2019542453A JP2019542453A JP2020506943A5 JP 2020506943 A5 JP2020506943 A5 JP 2020506943A5 JP 2019542453 A JP2019542453 A JP 2019542453A JP 2019542453 A JP2019542453 A JP 2019542453A JP 2020506943 A5 JP2020506943 A5 JP 2020506943A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- combination
- pharmaceutical composition
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700028369 Alleles Proteins 0.000 claims description 107
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 70
- 108091007433 antigens Proteins 0.000 claims description 70
- 102000036639 antigens Human genes 0.000 claims description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims description 55
- 230000000694 effects Effects 0.000 claims description 49
- 244000052769 pathogen Species 0.000 claims description 35
- 230000001717 pathogenic effect Effects 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 29
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 25
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 25
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 25
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 25
- 239000012190 activator Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 15
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102100038078 CD276 antigen Human genes 0.000 claims description 6
- 101710185679 CD276 antigen Proteins 0.000 claims description 6
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 claims description 6
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 6
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims description 6
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 6
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 208000008383 Wilms tumor Diseases 0.000 claims description 5
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 5
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 5
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 4
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 4
- 238000003782 apoptosis assay Methods 0.000 claims description 4
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000005522 programmed cell death Effects 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 2
- 101150051188 Adora2a gene Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 108700021638 Neuro-Oncological Ventral Antigen Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 description 13
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- -1 BTLA Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000829111 Human polyomavirus 1 Species 0.000 description 3
- 241000579048 Merkel cell polyomavirus Species 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010034145 Helminth Proteins Proteins 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455860P | 2017-02-07 | 2017-02-07 | |
| US62/455,860 | 2017-02-07 | ||
| PCT/US2018/016995 WO2018148183A1 (en) | 2017-02-07 | 2018-02-06 | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506943A JP2020506943A (ja) | 2020-03-05 |
| JP2020506943A5 true JP2020506943A5 (enExample) | 2021-02-25 |
Family
ID=61274340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542453A Pending JP2020506943A (ja) | 2017-02-07 | 2018-02-06 | 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200017586A1 (enExample) |
| EP (1) | EP3579846A1 (enExample) |
| JP (1) | JP2020506943A (enExample) |
| AU (1) | AU2018218221A1 (enExample) |
| CA (1) | CA3051869A1 (enExample) |
| WO (1) | WO2018148183A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| BR112021022458A2 (pt) | 2019-05-10 | 2021-12-28 | Univ California | Células pluripotentes modificadas ou uma célula derivada das mesmas, método de transplantar uma célula, método de tratamento de uma doença em um paciente em necessidade de células transplantadas, método para gerar uma célula pluripotente modificada, método para gerar uma célula hipoimunogênica pluripotente, e método de transplante de uma célula pluripotente hipoimunogênica (hip) ou célula derivada da mesma |
| US20220257757A1 (en) * | 2019-07-16 | 2022-08-18 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| JP2025513879A (ja) * | 2022-04-13 | 2025-04-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫チェックポイントエンゲージャーによる免疫細胞の抑制 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2079760T1 (sl) * | 2006-12-27 | 2016-11-30 | Emory University | Sestavki in metode za zdravljenje okužb |
| HUE028582T2 (en) * | 2008-11-28 | 2016-12-28 | Univ Emory | Method for determining the efficacy of PD-1 antagonists |
| CN105828834A (zh) * | 2013-11-05 | 2016-08-03 | 同源生物服务股份有限公司 | 检查点抑制剂和治疗剂的组合以治疗癌症 |
| CN119499280A (zh) | 2014-11-05 | 2025-02-25 | 纪念斯隆-凯特林癌症中心 | 选择用于过继细胞疗法的t细胞系及其供体的方法 |
| WO2016145578A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| WO2016174085A1 (en) * | 2015-04-27 | 2016-11-03 | Cancer Research Technology Limited | Method for treating cancer |
-
2018
- 2018-02-06 AU AU2018218221A patent/AU2018218221A1/en not_active Abandoned
- 2018-02-06 US US16/483,880 patent/US20200017586A1/en not_active Abandoned
- 2018-02-06 JP JP2019542453A patent/JP2020506943A/ja active Pending
- 2018-02-06 EP EP18707180.8A patent/EP3579846A1/en not_active Withdrawn
- 2018-02-06 WO PCT/US2018/016995 patent/WO2018148183A1/en not_active Ceased
- 2018-02-06 CA CA3051869A patent/CA3051869A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scully et al. | NK cells in HIV disease | |
| López-Botet et al. | The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection | |
| Weekes et al. | Human CD28− CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones | |
| Gillespie et al. | Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8+ T lymphocytes in healthy seropositive donors | |
| JP6995624B2 (ja) | 修正ガンマデルタｔ細胞およびその使用 | |
| Schub et al. | CMV-specific TCR-transgenic T cells for immunotherapy | |
| Saglio et al. | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care | |
| Retière et al. | Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response | |
| Sahu et al. | Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells | |
| Bollard et al. | Adoptive immunotherapy for posttransplantation viral infections | |
| Einsele et al. | CMV-specific T cell therapy | |
| Carayannopoulos et al. | Recognition of infected cells by natural killer cells | |
| AU2017330379B2 (en) | Generation and use in adoptive immunotherapy of stem cell-like memory T cells | |
| US20200182884A1 (en) | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses | |
| JP2020506943A5 (enExample) | ||
| US20220211759A1 (en) | Modulation of expression of genes related to t cell exhaustion | |
| Piersma et al. | Natural killer cell effector functions in antiviral defense | |
| Bjorgen et al. | NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics? | |
| Molloy et al. | Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus | |
| Scalzo et al. | Cmv1 and natural killer cell responses to murine cytomegalovirus infection | |
| Mehdizadeh et al. | Immunotherapy with adoptive cytomegalovirus‐specific T cells transfer: Summarizing latest gene engineering techniques | |
| US20200017586A1 (en) | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy | |
| Sellar et al. | The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation | |
| Nicholson et al. | Cytomegalovirus-specific T-cell therapies: current status and future prospects | |
| US20230405047A1 (en) | Methods and compositions for eliminating engineered immune cells |